Tagged: Acclaim-1

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer

Results from Phase 1 Portion Indicate Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial

Company has FDA Fast Track Designation for combination of REQORSA and Tagrisso

Multiple clinical trial sites to be opened under oncology research network collaboration

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial